Were Analysts Bullish Veracyte, Inc. (NASDAQ:VCYT) This Week?

March 20, 2018 - By Graig Alexander

 Were Analysts Bullish Veracyte, Inc. (NASDAQ:VCYT) This Week?
Investors sentiment decreased to 1.76 in 2017 Q3. Its down 0.12, from 1.88 in 2017Q2. It worsened, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Invesco Limited owns 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 11,336 shares. Board Of Trustees Of The Leland Stanford Junior University reported 12,500 shares stake. Axiom Ltd Company De has 388,328 shares. Ascend Cap Limited Liability owns 0.04% invested in Veracyte, Inc. (NASDAQ:VCYT) for 123,276 shares. Cortina Asset Mgmt Ltd Company holds 0.25% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 687,084 shares. Wells Fargo & Mn invested in 27,655 shares. Geode Lc, Massachusetts-based fund reported 156,423 shares. Millennium Mgmt Ltd Company invested 0.01% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Schwab Charles Mgmt reported 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Ajo L P owns 53,663 shares. Voya Invest Mgmt Ltd Co invested in 11,713 shares or 0% of the stock. Ny State Common Retirement Fund holds 25,200 shares or 0% of its portfolio. Tpg Group Hldg (Sbs) Advsrs invested in 3.55M shares or 0.5% of the stock. Da Davidson & stated it has 24,800 shares or 0% of all its holdings. Broadfin Capital Ltd Liability reported 1.02 million shares.

Since September 25, 2017, it had 0 buys, and 3 sales for $381,180 activity. Anderson Bonnie H also sold $50,624 worth of Veracyte, Inc. (NASDAQ:VCYT) on Monday, September 25.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, November 7 by Janney Capital. The firm has “Buy” rating by Janney Capital given on Tuesday, November 29. The firm earned “Buy” rating on Friday, December 18 by Cantor Fitzgerald. The stock of Veracyte, Inc. (NASDAQ:VCYT) earned “Outperform” rating by Leerink Swann on Tuesday, November 7. BTIG Research maintained Veracyte, Inc. (NASDAQ:VCYT) rating on Friday, August 14. BTIG Research has “Buy” rating and $13 target. The firm has “Hold” rating given on Tuesday, November 7 by Piper Jaffray. As per Friday, August 14, the company rating was maintained by Piper Jaffray. Below is a list of Veracyte, Inc. (NASDAQ:VCYT) latest ratings and price target changes.

07/11/2017 Broker: Piper Jaffray Rating: Hold Downgrade
07/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $12 New Target: $9 Maintain
07/11/2017 Broker: Janney Capital Old Rating: Buy New Rating: Neutral Downgrade
26/09/2017 Broker: Janney Capital Rating: Buy

The stock decreased 0.48% or $0.03 during the last trading session, reaching $6.16. About 79,658 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 20, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $211.23 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.